SEC Form 4 · accession 0001479290-19-000010
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cyril Allouche
Officer — Principal Accounting Officer
Period of report
Jan 22, 2019
Accepted (ET)
Jan 23, 2019 · 9:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2019 | M | 625 | $13.35 | A | 4,625 | D | |
| Common Stock | Jan 22, 2019 | S | 625 | $17.77 | D | 4,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $13.35 | Jan 22, 2019 | M | 625 | D | — | Oct 30, 2026 | Common Stock | 625 | 6,875 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.
- F2The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.